Clinical Trial Update: A Study of the Safety and Tolerability of V419 in Healthy Infants at 2,4, 6 and 12 to 14 Months of Age (V419-003) [Phase 2]

View source ↗

Summary

Phase 2 study assessing the safety and tolerability of V419 in healthy infants at 2, 4, 6, and 12-14 months of age.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bacterial Infections
• Viral Diseases

Drugs mentioned

• V419

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Bacterial Infections; Virus Diseases | Phase 2 | Status: COMPLETED